TABLE 1.
Patient demographic and clinical data summary
| Characteristic | Patient group value |
|||
|---|---|---|---|---|
| CF (n = 7) | Non-CF (n = 13) | Total (n = 20) | P | |
| Demographic data | ||||
| Mean age in yrs (range) | 36 (25–51) | 61 (28–77) | 52 (25–77) | 0.0006 |
| No. (%) of patients by age in yrs | 0.04 | |||
| ≥18 to <65 | 7 (100) | 7 (54) | 14 (70) | |
| ≥65 | 0 | 6 (46) | 6 (30) | |
| No. (%) of patients by gender | 0.07 | |||
| Female | 5 (71) | 3 (23) | 8 (40) | |
| Male | 2 (29) | 10 (76) | 12 (60) | |
| No. (%) of patients by race | 0.25 | |||
| Caucasian | 7 (100) | 10 (76) | 7 (85) | |
| Othera | 0 | 3 (23) | 3 (15) | |
| Clinical data | ||||
| Mean wt in kg (range) | 56.7 (41.6–68) | 78.2 (48.3–110) | 70.6 (41.6–110) | 0.01 |
| Mean daily dose of posaconazole in mgb (range) | 829 (400–1,200) | 862 (400–1,200) | 0.44 | |
| Feeding, no. (%) of patientsc | 0.14 | |||
| Regular feeding | 4 (57) | 11 (85) | 15 (75) | |
| Tube feeding | 2 (29) | 2 (15) | 4 (20) | |
| No feeding | 1 (14) | 0 (0) | 1 (5) | |
| Gastroesophageal reflux prophylaxis, no. (%) of patients | 0.63 | |||
| PPI | 4 (57) | 7 (54) | 11 (55) | |
| H2 antagonist | 3 (43) | 6 (47) | 9 (45) | |
a
Two patients were Hispanic, and one patient was Asian.
b
At the time of sample collection, patients received the following dosing regimens: 200 mg four times daily (n = 1), 200 mg twice daily (n = 3), 200 mg three times a day (n = 2), 400 mg twice daily (n = 10), and 400 mg three times a day (n = 4).
c
Posaconazole administration with a high-fat meal was recommended for all patients.